Testes de sensibilidade antimicrobiana de bactérias isoladas da córnea e da conjuntiva à moxifloxacina, gatifloxacina e outras fluoroquinolonas by Hofling-Lima, Ana Luisa et al.
Arq Bras Oftalmol. 2004;67(6):883-6
Testes de sensibilidade antimicrobiana de bactérias isoladas da córnea e da
conjuntiva à moxifloxacina, gatifloxacina e outras fluoroquinolonas
Trabalho realizado no Departamento de Oftalmologia
da Universidade Federal de São Paulo.
1 Prof(a). Titular do Departamento de Oftalmologia -
UNIFESP/EPM.
2 Médica do Departamento de Oftalmologia - UNIFESP/
EPM.
3 Doutor pelo Departamento de Oftalmologia - UNIFESP/
EPM.
4 Profª Afiliada do Departamento de Oftalmologia -
UNIFESP/EPM.
5 Livre Docente e Profª Afiliada do Departamento de
Oftalmologia - UNIFESP/EPM.
Endereço para correspondência: Av. Ibijaú, 331 -
4º Andar - São Paulo (SP) CEP 04524-020
Fone: 5055-1177/Fax: 5055-9557
E-mail: Ana@hoflinglima.med.br
Recebido para publicação em 05.09.2003
Versão revisada recebida em 24.05.2004
Aprovação em 23.07.2004
Ana Luisa Höfling-Lima1
Rubens Belfort Jr1
Cecília Tobias Aguiar Moeller2
Bruno Castelo Branco3
Luciene Barbosa de Sousa4
Denise de Freitas5
In vitro antibiotic susceptibilities of ocular bacteria
isolates from the cornea and conjunctiva to
moxifloxacin, gatifloxacin and other fluoroquinolones
Purpose: To assess and compare the in vitro susceptibility of ocular
bacterial isolates to fluoroquinolones, including moxifloxacin and gatiflo-
xacin. Methods: A total of 154 bacterial ocular isolates from keratitis and
conjunctivitis were tested for sensitivity to the studied antibiotics, using
the disk diffusion method. Results: Of the 51 corneal isolates, 46 (90.2%)
were sensitive to ciprofloxacin, 45 (88.2%) to ofloxacin and 41 (80.4%) to
lomefloxacin. All corneal isolates were sensitive to moxifloxacin and
gatifloxacin. Of the 103 bacterial conjunctival isolates, 101 (98.1%) and 103
(100%) were sensitive to gatifloxacin and moxifloxacin, respectively. Two
strains of Streptococcus sp viridans group were resistant to gatifloxacin.
A total of  82 (79.6%) specimens were sensitive to lomefloxacin, 89 (86.4%)
and 96 (93.2%) to ciprofloxacin and ofloxacin, respectively. Conclusions:
Fourth generation fluoroquinolones, herein exemplified by moxifloxacin
and gatifloxacin, seem to be more effective than previous generation
fluoroquinolones against frequently encountered organisms isolated from
patients with bacterial keratitis and conjunctivitis.
ABSTRACT
Keywords: Quinolones; Drug resistance, microbial; Eye infections, bacterial; Microbial
sensitivity tests; Cornea/microbiology; Conjunctiva/microbiology
INTRODUCTION
Ocular infections such as bacterial keratitis, conjunctivitis, and endoph-
thalmitis may represent a serious ocular problem with significant sight-
threatening consequences if aggressive, appropriate therapy is not promp-
tly instituted(1-5).
To minimize visual loss due to ocular infection, diagnosis has relied on
microbiology. Initial treatment with broad spectrum antibiotics is based on
the clinical picture(1-4), known pathogens and antibiotic sensitivities in a
given region(2,5).
For several years, fortified cephalosporins and aminoglycosides have
been used as first choice treatment for infectious keratitis. Problems asso-
ciated with topical fortified antibiotics such as local toxicity, stability, cost,
need for refrigeration and the emergence of antibiotic-resistant organisms
have prompted interest in the search for therapeutic alternatives(1,3,5-7).
The fluoroquinolones used as a single commercially available drug,
introduced for topical ophthalmic use in the mid-80 s, contributed to minimi-
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ze all those problems associated with topical fortified antibio-
tics and are also an alternative treatment combined with forti-
fied topical antibiotic in severe cases(3-6,8-10). This class of
antibiotic provides a broad-spectrum coverage against most
aerobic gram-negative and gram-positive bacteria and against
some anaerobic species(8,10-12). In addition, low toxicity, bacte-
ricidal effect, safety, good ocular penetration, and easy availa-
bility have made fluoroquinolones a good choice to treat
ocular infections(2,9,12).
Several clinical studies have demonstrated the efficacy of
fluoroquinolones in treating bacterial keratitis and conjuncti-
vitis(1,4,7,9,11-14). The first fluoroquinolone antibiotics formula-
ted for topical ophthalmic drops were ciprofloxacin, norfloxa-
cin and ofloxacin(6-7,9,12). However, emerging resistance to
fluoroquinolones and untoward effects associated with their
use, such as crystalline corneal deposits, reinforcing the need
to modify some structures of this class of antibiotics(2,4,6,10,13).
New generations of fluoroquinolones, such as gatifloxacin
and moxifloxacin, have been introduced to treat infections
caused by organisms resistant to the previous therapy(14-16).
Fourth generation fluoroquinolones possess an 8-metho-
xyside chain, which may be responsible for their enhanced
activity against gram-positive, atypical pathogens and broad-
spectrum coverage against gram-negative organisms. They
were primarily developed for the treatment of systemic infec-
tions such as pneumonia, and were also tested in ocular isola-
tes in several studies(14,17-18).
The study of oral administration of moxifloxacin or gatiflo-
xacin has made it possible to show therapeutic concentrations
in the aqueous humor(17-18). Studies performed to analyze in
vitro susceptibilities of these new fourth generation fluoro-
quinolones show an activity spectrum that appropriately
encompasses the bacterial species most frequently involved
in various causes of ocular infections(14-17,19-21).
The purpose of the present study was to assess in vitro
susceptibility of ocular bacterial isolates from conjunctiva and
cornea to moxifloxacin, gatifloxacin, and compare it to the pre-
vious fluoroquinolone generation, lomefloxacin, ciprofloxacin,
and ofloxacin. All tested microorganisms were isolated from a
population not exposed to fourth generation fluoroquinolones.
METHODS
We submitted to antibiotic susceptibility tests bacteria iso-
lated from patients with keratitis and conjunctivitis, examined
between July and November 2002 at the External Diseases Labo-
ratory at the Federal University of São Paulo, Brazil.
Material obtained from infected areas was cultured on
solid (blood, chocolate, Sabouraud’s, and nonnutrient agar)
and liquid media, (brain-heart infusion, and thioglycolate
broth). The laboratorial diagnosis was considered positive
when the same microorganism was observed on two or more
media, when there was confluent growth at the site of inocula-
tion on one solid media, or also when growth in one medium
was evidenced by consistent direct microscopy findings.
All isolates were subjected to in vitro antimicrobial sus-
ceptibility testing against moxifloxacin, gatifloxacin, lomeflo-
xacin, ciprofloxacin and ofloxacin, using the Kirby-Bauer disk
diffusion method. The reading was performed by measuring
the diameter of the inhibiting zone around the disk, in agree-
ment with the National Committee for Clinical Laboratory
Standards (NCCLS)(22) criteria for all antibiotics, with one of
three resulting grades: resistant, intermediately sensitive, or
susceptible (Table 1).
RESULTS
A total of 154 ocular pathogens from 94 patients with
culture-proven bacterial keratitis or conjunctivitis were isola-
ted. Susceptibility tests to the trial antibiotics were performed.
Of the 51 corneal isolates subjected to susceptibility tests,
33 (64.7%) were gram-positive cocci and 18 (35.3%) were gram-
negative bacilli. The most common microorganisms in de-
creasing order of frequency were coagulase-negative Staphy-
lococcus, Pseudomonas sp, Staphylococcus aureus and
Streptococcus pneumoniae (Table 2).
Of the 103 conjunctival isolates submitted to susceptibili-
ty tests, 87 (84.5%) were gram-positive cocci and 16 (15.5%)
were gram-negative bacilli. The most common isolates in de-
creasing order of frequency were: coagulase-negative Staphy-
Table 1. Grading of bacterial susceptibility to fluoroquinolones by the disk diffusion method according to the NCCLS criteria (São Paulo, Brazil)
Diameter of the inhibiting zone around the disk (mm)
Bacteria Gatifloxacin Moxifloxacin Lomefloxacin Ciprofloxacin Ofloxacin
R I S R I S R I S R I S R I S
Staphylococcus spp ≤ 14 15-17 ≥ 18 — — — ≤ 18 19-21 ≥ 22 ≤ 15 16-20 ≥ 21 ≤ 12 13-15 ≥ 16
Streptococcus sp viridans group ≤ 17 18-20 ≥ 21 — — — — — — — — — ≤ 12 13-15 ≥ 16
Streptococcus pneumoniae ≤ 17 18-20 ≥ 21 ≤ 14 15-17 ≥ 18 — — — — — — ≤ 12 13-15 ≥ 16
Pseudomonas spp ≤ 14 15-17 ≥ 18 — — — ≤ 18 19-21 ≥ 22 ≤ 15 16-20 ≥ 21 ≤ 12 13-15 ≥ 16
Haemophilus spp — — ≥ 18 — — ≥ 18 — — ≥ 22 — — ≥ 21 — — ≥ 16
Enterobacter spp ≤ 14 15-17 ≥ 18 — — — ≤ 18 19-21 ≥ 22 ≤ 15 16-20 ≥ 21 ≤ 12 13-15 ≥ 16
R: Resistant; I: Intermediate; S: Susceptible
1. For some organisms / antimicrobial combinations, the absence of resistant strains precludes defining any results category other than “susceptible”
2. The absence of any result for some antimicrobial defines that this antimicrobial is not commonly used for the bacteria selected
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lococcus, Staphylococcus aureus, Haemophilus sp and Strep-
tococcus sp viridans group (Table 3).
Overall susceptibilities of ciprofloxacin, ofloxacin and
lomefloxacin to microorganisms isolated from keratitis were,
90.2%, 88.2% and 80.4%, respectively. Moxifloxacin and
gatifloxacin were effective against all corneal isolates.
The same analysis performed of the conjunctival pathogens
revealed overall susceptibilities of ciprofloxacin, ofloxacin and
lomefloxacin of 86.4%, 93.2% and 79.6%, respectively. Gatifloxa-
cin and moxifloxacin showed antimicrobial sensitivities of
98.1% and 100%, respectively. Resistance to gatifloxacin was
observed in two strains of Streptococcus sp viridans group.
DISCUSSION
In our study, the fourth generation fluoroquinolones appear
to cover second-generation resistance among most Staphylo-
coccal species, S. viridans, and Pseudomonas. This finding is
supported by other studies with bacterial isolates from intraocu-
lar infections(14-16,19). These new fluoroquinolones show great
promise for treating ocular infections and may be an alternative to
prevent postsurgical endophthalmitis in special cases.
An experimental laboratory investigation revealed that
both moxifloxacin and gatifloxacin were more potent than the
second and third generation fluoroquinolones against gram-
positive bacteria and equally potent against gram-negative
bacteria(14). These results are in accordance with our study,
with the exception that both moxifloxacin and gatifloxacin also
displayed clearly improved activity against gram-negative
bacilli of ocular isolates.
The observed variation in susceptibility of Streptococcus sp
viridans group to one of the fourth generation fluoroquinolones,
in this study, may reflect established differences in the serum
standards for each of the fluoroquinolones. Since drug levels
attainable in the cornea are considerably higher than those in
Table 3. In vitro susceptibility of conjunctival bacterial isolated to antimicrobial agents
Susceptibility
Microorganism Total Gatifloxacin Moxifloxacin Lomefloxacin Ciprofloxacin Ofloxacin
N. N. (%) N. (%) N. (%) N. (%) N. (%)
Gram positive
Coagulase-negative Staphylococcus 55 55 100 55 100 50 90.9 50 90.9 52 94.5
Staphylococcus aureus 22 22 100 22 100 14 63.6 19 86.4 22 100
Streptococcus sp viridians group 8 6 75.0 8 100 3 37.5 2 25.0 6 75.0
Streptococcus pneumoniae 2 2 100 2 100 2 100 2 100 2 100
Total gram-positive microorganisms 87 85 97.7 87 100 69 79.3 73 83.9 82 94.3
Gram negative
Haemophilus sp 10 10 100 10 100 8 80.0 10 100 8 80.0
Serratia sp 2 2 100 2 100 2 100 2 100 2 100
Other gram-negative microorganisms * 4 4 100 4 100 3 75.0 4 100 4 100
Total gram-negative microorganisms 16 16 100 16 100 13 81.3 16 100 14 87.5
Grand Total 103 101 98.1 103 100 82 79.6 89 86.4 96 93.2
* Neisseria sp (2), Moraxella sp (1), and Klebsiella sp (1)
Table 2. In vitro susceptibility of corneal bacterial isolated to antimicrobial agents
Susceptibility
Microorganism  Total Gatifloxacin Moxifloxacin Lomefloxacin Ciprofloxacin Ofloxacin
N. N. (%) N. (%) N. (%) N. (%) N. (%)
Gram positive
Coagulase-negative Staphylococcus 22 22 100 22 100 19 86.4 19 86.4 18 81.8
Staphylococcus aureus 5 5 100 5 100 5 100 5 100 5 100
Streptococcus pneumoniae 5 5 100 5 100 3 60.0 5 100 4 80.0
Streptococcus sp viridians group 1 1 100 1 100 0 0 0 0 1 100
Total gram-positive microorganisms 33 33 100 33 100 27 81.8 29 87.9 28 84.8
Gram negative
Pseudomonas sp 7 7 100 7 100 5 71.4 6 85.7 6 85.7
Moraxella sp 3 3 100 3 100 3 100 3 100 3 100
Other gram-negative microorganisms * 8 8 100 8 100 6 75.0 7 87.5 7 87.5
Total gram-negative microorganisms 18 18 100 18 100 14 80.4 17 94.4 17 94.4
Grand Total 51 51 100 51 100 41 80.4 46 90.2 45 88.2
* Serratia sp (2), Haemophilus sp (2) Pseudomonas aeruginosa (1), Providencia sp (1), Morganella morganii (1), and Citrobacter sp (1)
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serum, disc diffusion methods tend to overestimate resistance for
ocular pathogens, from a clinical standpoint. However, results
encountered may reflect a plasmid-mediated resistance, once the
fourth generation fluoroquinolones were developed to resist
spontaneous mutations, and generally two genetic mutations are
required for changes in antibiotic susceptibility to occur with
fourth generation fluoroquinolones(14).
Initial results from this in vitro study of corneal and con-
junctival bacterial isolates show forthcoming advantage of
fourth generation fluoroquinolones over second generation
as demonstrated with the broad spectrum activity observed
for gram-positive cocci, gram-negative bacilli and anaerobic
microorganisms(15-18,23).
One of the limitations of using in vitro antimicrobial sus-
ceptibility testing as a surrogate for in vivo effectiveness is
that although a favorable clinical result is not guaranteed, it
does provide an indication of the potential susceptibility of
the microorganism in vivo. Ongoing therapy still should be
guided by assessment of the patient’s clinical response.
CONCLUSION
As recommended the key parameter to consider in the
comparison of antibiotic potency is the MIC value; therefore,
further tests are necessary to complete this evaluation.
A new possibility for treating ocular infections and pre-
venting postsurgical endophthalmitis considering cost and
benefit must be analyzed. In order to avoid development of
resistance, the use has to be analyzed considering that se-
cond generation fluoroquinolones still remain effective
against most ocular bacterial isolates.
RESUMO
Objetivos: Conhecer e comparar a susceptibilidade in vitro de
bactérias isoladas do olho à fluoroquinolonas, incluindo
moxifloxacina e gatifloxacina. Métodos: Um total de 154 bacté-
rias isoladas de ceratites e conjuntivites foram submetidas a
testes de sensibilidade antimicrobiana aos antibióticos usan-
do o método de difusão em disco. Resultados: Das 51 bacté-
rias isoladas da córnea, 46 (90,2%) foram sensíveis a ciproflo-
xacina, 45 (88,2%) a ofloxacina e 41 (80,4%) a lomefloxacina.
Todas as bactérias isoladas da córnea foram sensíveis a
moxifloxacina e a gatifloxacina. Das 103 bactérias isoladas da
conjuntiva 101 (98,1%) e 103 (100%) foram sensíveis a gati-
floxacina e moxifloxacina, respectivamente. Duas cepas de
Streptococcus sp do grupo viridans mostraram-se resistentes
à gatifloxacina. Um total de 82 (79,6%) espécimes foi sensível a
lomefloxacina, 89 (86,4%) e 96 (93,2%) a ciprofloxacina e
ofloxacina, respectivamente. Conclusões: As quinolonas de
4ª geração, aqui exemplificadas pela moxifloxacina e gatifloxa-
cina, apresentam eficácia antimicrobiana maior do que a cipro-
floxacina, ofloxacina e lomefloxacina contra os organismos
freqüentemente isolados em pacientes com infecções bacte-
rianas da córnea e da conjuntiva.
Descritores: Quinolonas; Resistência microbianas a drogas;
Infecções oculares bacterianas; Testes de sensibilidade mi-
crobiana; Córnea/microbiologia; Conjuntiva/microbiologia
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